Kidswell Bio Corporation (4584) Consolidated Financial Results for 1QFY2021

August 12, 2021

Summary of Consolidated Financial Results
for the First Quarter of the Fiscal Year Ending March 31, 2022
Company name:
Stock code:
Representative:
Contact:

Kidswell Bio Corporation
4584
Masaharu Tani, President & CEO
Yasuo Sakae, Corporate Officer, CFO
Tel: +81-3-6222-9547
Scheduled date of filing of Quarterly Securities Report:
Scheduled date of payment of dividend:
Preparation of supplementary materials for financial results:
Briefing of the quarterly financial results[Japanese GAAP]

Listing: Tokyo Stock Exchange
URL: https://www.kidswellbio.com/en/

August 13, 2021
YesNone(All amounts are rounded down to the nearest million yen)
1. Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022
(April 1, 2021 – June 30, 2021)(1) Results of operations (cumulative)(Percentages shown for net sales and incomes represent year-on-year changes)
Net income
Net sales
Operating income
Ordinary income
attributable to ownersof the parent
Million yen%

Million yen%

Million yen%

Million yen%--313--314---244--244-First quarter of the fiscal year
303
150.1
-309
ending Mar. 31, 2022
First quarter of the fiscal year
121-57.3-237
ended Mar. 31, 2021
(Note) Comprehensive income
First quarter of the fiscal year ending Mar. 31, 2022: -216 million yen (-%)
First quarter of the fiscal year ended Mar. 31, 2021: -164 million yen (-%)
Net income
per share

Diluted net income
per share
YenYenFirst quarter of the fiscal year
-10.50ending Mar. 31, 2022
First quarter of the fiscal year
-8.72
ended Mar. 31, 2021
(Note) Even though there is a calculation of dilutive shares available, there is no reporting on quarterly net income per share after anadjustment of dilutive shares as the company recorded net loss.
(2) Financial position
Total assets
Million yen

Million yen%

1,648
1,610

43.0
38.0

As of June 30, 2022
3,521
As of Mar. 31, 2021
3,933
(Reference) Shareholders’ equity
First quarter of the fiscal year ending Mar. 31, 2022: 1,513 million yen,
Fiscal year ended Mar. 31, 2021: 1,494 million yen
2.

Shareholders’equity ratio

Net assets

Dividends
Dividend per share
1Q-end 2Q-end 3Q-end Year-endYen

Yen

Yen

TotalYen

Yen

Fiscal year ended Mar. 31, 2021
0.00
0.00
Fiscal year ending Mar. 31, 2022
Fiscal year ending Mar. 31, 2022
0.00
0.00
(forecasts)(Note) Changes to the most recent forecasted dividend amount: None

0.00
0.00

1

Kidswell Bio Corporation (4584) Consolidated Financial Results for 1QFY2021

3.

Consolidated Business Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 – March 31, 2022)(Percentages represent year-on-year changes)

Net sales
Million yen%

Operating income

Ordinary income

Million yen

Million yen%

Net income
attributable toowners of the parent%

Net income
per share

Million yen%

Yen

1,900
90.7
-1,720-1,740-1,741
Full year(Note) Changes to the most recent forecasted dividend amount: None
Full-year performance forecast is shown because the company mainly manages annual performance.

--57.50* Notes1.

Changes in significant subsidiaries during the period (change in specified subsidiaries which accompanies a change in the rangeof consolidation): None2.

Special accounting treatments used in preparation of financial statements of the quarter: None

3.

Changes in accounting policies and accounting-based estimates, and restatements

a. Changes in accounting policies due to revisions in accounting standards, others: Yes
b. Changes in accounting policies other than a) above: Nonec. Changes in accounting-based estimates: None
d. Restatements: None
3. Number of outstanding shares (common stock)a. Number of shares outstanding at the end of period (including treasury shares)
At the end of the first quarter of the fiscal year ending Mar. 31, 2022: 30,174,047 shares
At the end of the fiscal year ended Mar. 31, 2021: 29,622,847 sharesb. Number of treasury shares at the end of period
At the end of the first quarter of the fiscal year ending Mar. 31, 2022: 92 shares
At the end of the fiscal year ended Mar. 31, 2021: 92 sharesc. Average number of shares outstanding during the period (Quarter-to-date)
At the end of the first quarter of the fiscal year ending Mar. 31, 2022: 29,912,862 shares
At the end of the first quarter of the fiscal year ended Mar. 31, 2021: 28,079,213 shares*This summary report on Kidswell Bio Corporation’s financial statements is not subject to audit procedures.
Cautionary statement with respect to forward-looking statements, and other special items(Notes to information regarding future)
The statement regarding the future such as business forecasts in this summary is based on assumptions judged to be valid and theinformation available to Kidswell Bio at the time this summary was made and is not promised by the Company.
(How to obtain supplemental financial information)
Materials for the supplemental financial information is available on the Company’s website (https://www.kidswellbio.com/en/).

2Kidswell Bio Corporation (4584) Consolidated Financial Results for 1QFY2021○Table of Contents of the Attachment
I. Financial statements and notes to financial statements………………………………………………………………………
(A) Quarterly consolidated balance sheet………………………………………………………………………………………
(B) Statement of consolidated income and comprehensive income……………………………………………………………

4453

Kidswell Bio Corporation (4584) Consolidated Financial Results for 1QFY2021

I. Financial statements and notes to financial statements(A) Quarterly consolidated balance sheetAs of the end of the previous
fiscal year(March 31, 2021)
AssetsCurrent assets
Cash and cash equivalents
Trade receivables
Products
In-process inventory
Advance payments
Other current assets
Total current assets
Non-current assets
Tangible fixed assets
Intangible fixed assets
Investments and other assets
Investment securities
Other assets
Total investments and other assets
Total non-current assets
Total assets
Liabilities
Current liabilities
Trade payables
Income taxes payable
Reserve for loss on orders
Other current liabilities
Total current liabilities
Non-current liabilities
Convertible bonds
Long-term debts
Allowance for retirement benefits
Other non-current liabilities
Total non-current liabilities
Total liabilities
Shareholders’ equity
Shareholders' capital
Common stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders capital
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Total accumulated other comprehensive income
Equity warrants
Total shareholders’ equity
Total liabilities and shareholders’ equity(In thousand yen)
As of the end of the current fiscalquarter(June 30, 2021)

1,461,158
816,737
70,712
380,039431,718
185,943
3,346,310

874,398
578,941
117,564583,506
486,386
153,348
2,794,146

3,223
2,622

2,824
2,450

563,159
18,636
581,795
587,641
3,933,952

703,726
18,531
722,258
727,532
3,521,678

109,739
28,461
379,243596,875
1,114,319

14,573
15,608475,243
317,517822,941

500,000
600,000
19,75589,491
1,209,246
2,323,566

300,000
600,000
18,045132,505
1,050,550
1,873,492

1,032,179
10,337,779-10,078,706-73
1,291,179

1,150,275
10,455,876-10,392,728-73
1,213,350

202,965
202,965
116,240
1,610,385
3,933,952

300,519
300,519
134,317
1,648,186
3,521,678

4

Kidswell Bio Corporation (4584) Consolidated Financial Results for 1QFY2021(B) Statement of consolidated income and comprehensive income(Statement of consolidated income)(Quarterly consolidated cumulative period)(In thousand yen)
As of the end of the previous
fiscal quarter(April 1 to June 30, 2020)
Gross sales
Cost of goods sold
Gross profit
Selling, general and administrative expenses
Research and development expenses
Other expenses
Total selling, general and administrative expenses
Operating loss
Non-operating income
Interest income
Foreign exchange gain
Income from sale of materials
Miscellaneous income
Total non-operating income
Non-operating expenses
Interest expense
Stock issuance expenses
Foreign exchange loss
Miscellaneous loss
Total non-operating expenses
Ordinary loss
Extraordinary loss
Loss on retirement of fixed assets
Total extraordinary loss
Net loss for the quarter before taxes adjustments
Corporate, residential and enterprise taxes
Total corporate and other taxes
Net loss for the quarterNet loss attributable to owners of the parents

As of the end of the current
fiscal quarter(April 1 to June 30, 2021)

121,294
4,971
116,322

303,367
121,792
181,574

138,411
215,668
354,080-237,757

296,718
194,083
490,802-309,227

24
152－
213
391

2
－
1,500
27
1,530

4,052
2,417
－
505
6,975
-244,341

3,882
1,308
758
－
5,949
-313,64600-244,341
515
515-244,857-244,857－－-313,646
375
375-314,021-314,021

5

Kidswell Bio Corporation (4584) Consolidated Financial Results for 1QFY2021(Statement of consolidated comprehensive income）(Quarterly consolidated cumulative period）(In thousand yen)

Net loss for the quarter

As of the end of the previous

As of the end of the current

fiscal quarterfiscal quarter(April 1 to June 30, 2020)(April 1 to June 30, 2021)-244,857-314,021

Valuation difference on available-for-sale securities

80,311

97,553

Total other comprehensive income

80,311

97,553Comprehensive income for the quarter-164,545-216,467-164,545-216,467－－

Other comprehensive income(Breakdown)Comprehensive income attributable to owners of theparent
Comprehensive income attributable to non-controllinginterests6